EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 49 / No 3 (September 2017) J Extra Corpor Technol, 49 3 (2017) 150-159 References
Free Access
Issue
J Extra Corpor Technol
Volume 49, Number 3, September 2017
Page(s) 150 - 159
DOI https://doi.org/10.1051/ject/201749150
Published online 15 September 2017
  1. Amaker RD, DiPiro JT, Bhatia J Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996;40:1139–42. [CrossRef] [PubMed] [Google Scholar]
  2. Buck ML Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1998;18:1082–6. [PubMed] [Google Scholar]
  3. Donadello K, Roberts JA, Cristallini S, et al. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: A matched cohort study. Crit Care. 2014;18:632. [CrossRef] [PubMed] [Google Scholar]
  4. Mulla H, Pooboni S Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005;60:265–75. [CrossRef] [PubMed] [Google Scholar]
  5. Bhatt-Mehta V, Johnson CE, Schumacher RE Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1992;12:28–32. [PubMed] [Google Scholar]
  6. Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J. 1990;9:562–6. [CrossRef] [PubMed] [Google Scholar]
  7. Munzenberger PJ, Massoud N Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans. 1991;37:16–8. [CrossRef] [PubMed] [Google Scholar]
  8. Southgate WM, DiPiro JT, Robertson AF Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1989;33:817–9. [CrossRef] [PubMed] [Google Scholar]
  9. Watt KM, Gonzalez D, Benjamin DKJr, et al. Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2015;59:3935–43. [CrossRef] [PubMed] [Google Scholar]
  10. Leuschen MP, Willett LD, Hoie EB, et al. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 1993;105:885–91. [PubMed] [Google Scholar]
  11. Dagan O, Klein J, Bohn D, Koren G Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med. 1994;22:1099–101. [CrossRef] [PubMed] [Google Scholar]
  12. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin Pharmacokinet. 2006;45:705–14. [CrossRef] [PubMed] [Google Scholar]
  13. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med. 2005;31:257–63. [CrossRef] [PubMed] [Google Scholar]
  14. Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet. 2010;49:407–19. [CrossRef] [PubMed] [Google Scholar]
  15. Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology. 2003;99:275–82. [CrossRef] [PubMed] [Google Scholar]
  16. Harthan AA, Buckley KW, Heger ML, Fortuna RS, Mays K Medication adsorption into contemporary extracorporeal membrane oxygenator circuits. J Pediatr Pharmacol Ther. 2014;19:288–95. [PubMed] [Google Scholar]
  17. Preston TJ, Hodge AB, Riley JB, Leib-Sargel C, Nicol KK In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol. 2007;39:234–7. [PubMed] [Google Scholar]
  18. Preston TJ, Ratliff TM, Gomez D, et al. Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. J Extra Corpor Technol. 2010;42:199–202. [PubMed] [Google Scholar]
  19. Palmgren JJ, Monkkonen J, Korjamo T, Hassinen A, Auriola S Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm. 2006;64:369–78. [CrossRef] [PubMed] [Google Scholar]
  20. Unger JK, Kuehlein G, Schroers A, Gerlach JC, Rossaint R Adsorption of xenobiotics to plastic tubing incorporated into dynamic in vitro systems used in pharmacological research–limits and progress. Biomaterials. 2001;22:2031–7. [CrossRef] [PubMed] [Google Scholar]
  21. Marchal-Heussler L, Barra J Adsorption of Drugs. In: Hubbard AT, ed. Encyclopedia of Surface and Colloid Science, vol 1. New York: Marcel Dekker; 2002:294–306. [Google Scholar]
  22. Shekar K, Fraser JF, Taccone FS, et al. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: A matched cohort study. Crit Care. 2014;18:565. [CrossRef] [PubMed] [Google Scholar]
  23. Shekar K, Roberts JA, McDonald CI, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16:R194. [CrossRef] [PubMed] [Google Scholar]
  24. Shekar K, Roberts JA, McDonald CI, et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: Results from an ex vivo study. Crit Care. 2015;19:164. [CrossRef] [PubMed] [Google Scholar]
  25. Lemaitre F, Hasni N, Leprince P, et al. Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care. 2015;19:40. [CrossRef] [PubMed] [Google Scholar]
  26. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2010;54:1734–41. [CrossRef] [PubMed] [Google Scholar]
  27. van der Vorst MM, Wildschut E, Houmes RJ, et al. Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation. Crit Care. 2006;10:R168. [CrossRef] [PubMed] [Google Scholar]
  28. Wildschut ED, de Hoog M, Ahsman MJ, Tibboel D, Osterhaus AD, Fraaij PL Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One. 2010;5:e10938. [CrossRef] [PubMed] [Google Scholar]
  29. Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH Potential drug sequestration during extracorporeal membrane oxygenation: Results from an ex vivo experiment. Intensive Care Med. 2007;33:1018–24. [CrossRef] [PubMed] [Google Scholar]
  30. Mulla H, Lawson G, von Anrep C, et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion. 2000;15:21–6. [CrossRef] [PubMed] [Google Scholar]
  31. Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36:2109–16. [CrossRef] [PubMed] [Google Scholar]
  32. Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. 2011;12:277–81. [CrossRef] [PubMed] [Google Scholar]
  33. Arredondo G, Calvo R, Marcos F, Martinez-Jorda R, Suarez E Protein binding of itraconazole and fluconazole in patients with cancer. Int J Clin Pharmacol Ther. 1995;33:449–52. [PubMed] [Google Scholar]
  34. Arredondo G, Martinez-Jorda R, Calvo R, Aguirre C, Suarez E Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther. 1994;32:361–4. [PubMed] [Google Scholar]
  35. European Medicines Agency. Assessment Report for Mycamine. London: European Medicines Agency; 2008. [Google Scholar]
  36. U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD; 2013. [Google Scholar]
  37. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit. 1993;15:263–6. [CrossRef] [PubMed] [Google Scholar]
  38. Hirata K, Aoyama T, Matsumoto Y, et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi. 2007;127:897–901. [CrossRef] [PubMed] [Google Scholar]
  39. Maseda E, Grau S, Villagran MJ, et al. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. J Antimicrob Chemother. 2014;69:1624–32. [CrossRef] [PubMed] [Google Scholar]
  40. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun. 2004;72:6023–31. [CrossRef] [PubMed] [Google Scholar]
  41. Eppes SC, Troutman JL, Gutman LT Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J. 1989;8:99–104. [Google Scholar]
  42. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35. [CrossRef] [PubMed] [Google Scholar]
  43. Kaneko Y, Ohno H, Fukazawa H, et al. Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses. Med Mycol. 2010;48:606–12. [CrossRef] [PubMed] [Google Scholar]
  44. Autmizguine J, Hornik CP, Benjamin DKJr, et al. Pharmacokinetics and safety of micafungin in infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J. 2016;35:1204–10. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.